Literature DB >> 16316630

Evaluation of viral and mammalian promoters for driving transgene expression in mouse liver.

Mohammed Al-Dosari1, Guisheng Zhang, Joseph E Knapp, Dexi Liu.   

Abstract

Fifteen luciferase plasmid constructs driven by various promoters including cytomegalovirus (CMV), Rous sarcoma virus (RSV), human serum albumin (SA), alpha-1 antitrypsin (AAT), cytochrome P450 CYP1A2, CYP2C9, CYP2C18, CYP2D6, CYP3A4, mouse CYP2b10, human amyloid precursor protein (APP), chicken beta actin (ACT), nuclear factor kappa B (NFkappaB), and heat shock protein 70 (HS) promoters were hydrodynamically introduced into mouse hepatocytes, and the level and persistence of luciferase gene expression were examined. Eight hours post-gene transfer, the CMV and AAT promoters showed the highest activity, followed by the CYP2D6, HS, and RSV promoters which were slightly less active. The human serum albumin promoter exhibited the lowest activity among the promoters examined. The time course of gene expression showed a two-phase decline in luciferase activity with a rapid phase within the first 5-7 days and a slower decline thereafter. Results from Southern and Northern blot analyses revealed a good correlation between the decline of luciferase activity and the decrease in mRNA level, suggesting promoter silencing as the possible mechanism for the observed transient luciferase gene expression. Inclusion of EBN1 and oriP sequences of Epstein-Barr virus into the plasmid extended the period of active transcription for about one week. These results provide important information concerning the role of promoters in regulating transgene expression and for the proper design of plasmids for gene expression and gene therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16316630     DOI: 10.1016/j.bbrc.2005.11.063

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

1.  Secreted luciferase for in vivo evaluation of systemic protein delivery in mice.

Authors:  Salim S El-Amouri; Phuong Cao; Carol Miao; Dao Pan
Journal:  Mol Biotechnol       Date:  2013-01       Impact factor: 2.695

Review 2.  Gene therapy for liver regeneration: experimental studies and prospects for clinical trials.

Authors:  Hussein-M Atta
Journal:  World J Gastroenterol       Date:  2010-08-28       Impact factor: 5.742

3.  The dynamic impact of hydrodynamic gene transfer on the immune system.

Authors:  Yan Wu; Shoubao Ma; Yonghao Liu; Lei Lei; Bo Hu; Haiyan Liu
Journal:  Int J Clin Exp Med       Date:  2015-06-15

4.  Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B.

Authors:  Ru Zhang; Qiang Wang; Lin Zhang; Saijuan Chen
Journal:  Front Med       Date:  2015-02-07       Impact factor: 4.592

5.  The Pacific White Shrimp β-actin Promoter: Functional Properties and the Potential Application for Transduction System Using Recombinant Baculovirus.

Authors:  Yingli Shi; Jianhai Xiang; Guangzhou Zhou; Tetsuzan Benny Ron; Hsin-I Tong; Wen Kang; Si Sun; Yuanan Lu
Journal:  Mar Biotechnol (NY)       Date:  2016-05-13       Impact factor: 3.619

6.  Delivery of an EBV episome by a self-circularizing helper-dependent adenovirus: long-term transgene expression in immunocompetent mice.

Authors:  J S Gil; S D Gallaher; A J Berk
Journal:  Gene Ther       Date:  2010-05-13       Impact factor: 5.250

7.  A simple and rapid nonviral approach to efficiently transfect primary tissue-derived cells using polyethylenimine.

Authors:  Charlie Yu Ming Hsu; Hasan Uludağ
Journal:  Nat Protoc       Date:  2012-04-19       Impact factor: 13.491

Review 8.  Nonviral gene transfer as a tool for studying transcription regulation of xenobiotic metabolizing enzymes.

Authors:  Barbara Bonamassa; Dexi Liu
Journal:  Adv Drug Deliv Rev       Date:  2010-08-14       Impact factor: 15.470

9.  Bioinformatics in new generation flavivirus vaccines.

Authors:  Penelope Koraka; Byron E E Martina; Albert D M E Osterhaus
Journal:  J Biomed Biotechnol       Date:  2010-05-10

10.  Treatment of diabetes and long-term survival after insulin and glucokinase gene therapy.

Authors:  David Callejas; Christopher J Mann; Eduard Ayuso; Ricardo Lage; Iris Grifoll; Carles Roca; Anna Andaluz; Rafael Ruiz-de Gopegui; Joel Montané; Sergio Muñoz; Tura Ferre; Virginia Haurigot; Shangzhen Zhou; Jesús Ruberte; Federico Mingozzi; Katherine A High; Felix Garcia; Fatima Bosch
Journal:  Diabetes       Date:  2013-02-01       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.